This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Can Lilly's Next-Gen Obesity Drugs Help Sustain Its Market Dominance?
by Kinjel Shah
Eli Lilly's next-gen obesity drugs, led by oral orforglipron and triple-acting retatrutide, aim to reshape the fast-growing weight-loss market.
NVONegative Net Change LLYNegative Net Change AMGNNegative Net Change VKTXNegative Net Change
pharmaceuticals
GILD's Investigational Regimen for HIV Treatment Meets Primary Goal
by Zacks Equity Research
Gilead's ARTISTRY-1 success boosts shares as its once-daily bictegravir/lenacapavir combo proves non-inferior to complex regimens.
GSKNegative Net Change ALKSNegative Net Change GILDNegative Net Change FOLDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Zacks Investment Ideas feature highlights: IWM, CoreWeave, Astera Labs, Nebius, Expand Energy, Eli Lilly and Nvidia
by Zacks Equity Research
Zacks Investment Ideas tracks market shifts as IWM strength, AI stock rotation and Nvidia's key support test shape year-end positioning.
LLYNegative Net Change NVDANegative Net Change IWMPositive Net Change ALABNegative Net Change NBISNegative Net Change EXENegative Net Change CRWVPositive Net Change
alt-energy computers etfs pharmaceuticals semiconductor tech-stocks
Cytokinetics Gains 11.4% in a Week: Is There More Room for Growth?
by Zacks Equity Research
Cytokinetics' shares surge to a 52-week high as investor optimism grows over FDA approval prospects for aficamten.
BMYNegative Net Change ALKSNegative Net Change FOLDNegative Net Change CYTKNegative Net Change
biotechnology biotechs medical pharmaceuticals
BMY's Growth Portfolio Shines in Q3: Turning Point Ahead?
by Ekta Bagri
Bristol Myers' strong Q3 growth portfolio, led by Opdivo and Reblozyl, helped counter declines in legacy drug sales.
BMYNegative Net Change PFENegative Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint
by Zacks Equity Research
NVS' GanLum meets its phase III goal, showing strong efficacy against drug-resistant malaria and proving non-inferiority to the current standard of care.
NVSPositive Net Change ANIPPositive Net Change ADMAPositive Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
New Strong Sell Stocks for Nov. 13
by Zacks Equity Research
AMRK, ALVO and GPK have been added to the Zacks Rank #5 (Strong Sell) List on Nov. 13, 2025.
GPKNegative Net Change ALVOPositive Net Change
pharmaceuticals
Bayer Q3 Earnings Beat Estimates on Crop Science Business Gains
by Zacks Equity Research
Bayer's Q3 earnings surged on Crop Science strength, offsetting pricing and currency headwinds across divisions.
REGNNegative Net Change JNJNegative Net Change BAYRYPositive Net Change
biotechnology earnings medical pharmaceuticals
How Much Did Skyrizi and Rinvoq Drive AbbVie's Q3 Performance?
by Sundeep Ganoria
ABBV's growth engine keeps humming as Skyrizi and Rinvoq together now power more than 40% of total revenues and drive new market share gains.
JNJNegative Net Change LLYNegative Net Change ABBVNegative Net Change
biotechs earnings medical pharmaceuticals
Company News for Nov 12, 2025
by Zacks Equity Research
Companies in The News Are: SONY, SE, NVDA, LLY
LLYNegative Net Change NVDANegative Net Change SEPositive Net Change SONYPositive Net Change
consumer-discretionary pharmaceuticals semiconductor
Can NVO's Ozempic, Wegovy Sales Improve in 2026 After a Subdued Q3?
by Ahan Chakraborty
Novo Nordisk eyes a 2026 comeback as it slashes jobs, cuts U.S. semaglutide prices and focuses on expanding the reach of key drugs after a weak Q3.
NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
J&J's MedTech Unit Sales Improve: Will the Momentum Last?
by Kinjel Shah
J&J's MedTech sales rose 5.6% in Q3, fueled by cardiovascular strength and strategic portfolio shifts toward high-growth markets.
ABTNegative Net Change JNJNegative Net Change MDTNegative Net Change SYKNegative Net Change
pharmaceuticals
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus
by Zacks Equity Research
Immunovant posts a wider Q2 loss as R&D spending rises, but progress on IMVT-1402 and batoclimab fuels its pipeline momentum.
ALKSNegative Net Change FOLDNegative Net Change CRMDPositive Net Change IMVTNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y
by Zacks Equity Research
EDIT reports narrower Q3 loss, boosts revenues on a Bristol Myers milestone, and advances in vivo gene-editing program with EDIT-401.
ANIPPositive Net Change ADMAPositive Net Change EDITPositive Net Change ARQTNegative Net Change
biotechnology biotechs earnings gene-editing medical pharmaceuticals
Lilly Up 18% in a Month: Should You Buy, Sell or Hold the Stock?
by Kinjel Shah
Eli Lilly stock jumps 18% in a month as strong Q3 results, upgraded guidance and rising demand for Mounjaro and Zepbound fuel investor optimism.
NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change ADVMNo Net Change
pharmaceuticals
CRSP Posts Narrower-Than-Expected Loss in Q3, Sales Miss Estimates
by Zacks Equity Research
CRISPR Therapeutics posts a narrower-than-expected Q3 loss, trims R&D spend, and advances late-stage and next-gen gene-editing programs.
ALKSNegative Net Change VRTXNegative Net Change CRMDPositive Net Change CRSPNegative Net Change
biotechs crispr earnings gene-editing gene-therapy medical pharmaceuticals
Top Research Reports for Accenture, Sanofi & Dell Technologies
by Mark Vickery
Accenture, Sanofi, and Dell Technologies stand out in today's top analyst research picks, each navigating growth and market pressures in distinct ways.
SNYNegative Net Change ACNPositive Net Change PEGPositive Net Change PCGPositive Net Change DELLNegative Net Change CVENegative Net Change
computers pharmaceuticals
Will Lower GLP-1 Prices Undermine Novo Nordisk's Near-Term Outlook?
by Ahan Chakraborty
NVO's new U.S. pricing deal for Ozempic and Wegovy expands access but adds uncertainty to its growth and profit outlook.
NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Will Keytruda Aid MRK's Growth in 2026 After a Subdued Q3?
by Kanishka Das
Merck leans on Keytruda's expanding cancer indications and new SC formulation to sustain growth momentum into 2026 after soft sales in Q3.
MRKNegative Net Change MRNAPositive Net Change SMMTNegative Net Change
pharmaceuticals
Pfizer Wins Obesity War Against NVO, to Buy Metsera for Around $10B
by Kinjel Shah
Pfizer secures a $10B deal to buy Metsera, ending its fierce bidding war with Novo Nordisk and reigniting its push into the obesity market.
PFENegative Net Change NVONegative Net Change
pharmaceuticals
Bristol Myers Gains 7.2% in a Month: Buy, Sell or Hold the Stock?
by Ekta Bagri
Bristol Myers Squibb's strong Q3 driven by soaring demand for Opdivo, Reblozyl, Breyanzi and Camzyos pushes shares up 7.2% in a month.
BMYNegative Net Change PFENegative Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Does Trump's MFN Policy Put Pharma ETFs in the Crosshairs?
by Aparajita Dutta
With Trump's MFN policy cutting U.S. drug prices, will Pharma ETFs such as IHE, heavily weighted toward Eli Lilly and Novo Nordisk, lose momentum?
PFENegative Net Change NVONegative Net Change LLYNegative Net Change ABBVNegative Net Change PJPNegative Net Change IHENegative Net Change PPHNegative Net Change
etfs pharmaceuticals
DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug
by Zacks Equity Research
Denali's Q3 loss widens year over year as expenses rise, while the FDA delays its review of the firm???s key Hunter syndrome therapy to 2026.
BIIBNegative Net Change ALKSNegative Net Change DNLINegative Net Change TAKPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Pfizer Discusses Drug Pricing Deal, Metsera Buyout Dispute on Q3 Call
by Kinjel Shah
Pfizer faces a fierce bidding war with Novo Nordisk over Metsera while securing a landmark U.S. drug pricing deal.
AZNNegative Net Change PFENegative Net Change NVONegative Net Change
pharmaceuticals
LLY's GLP-1 Duo Boosts Sales Amid Rising Demand for Obesity Drugs
by Kinjel Shah
Lilly's Mounjaro and Zepbound continue to power growth as new launches boost momentum amid rising obesity competition.
PFENegative Net Change NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change
pharmaceuticals